We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 53

A balancing act: innovation and the regulatory-approval exemption
  • Gowling WLG
  • Canada
  • April 22 2013

In the pharmaceutical sector, patent systems are concerned with balancing the interests of innovator drug companies, the public and generic


Data protection in Canada: too much? Too little?
  • Gowling WLG
  • Canada
  • June 28 2011

Prior to the enactment in 2006 of the amendments to section C.08.004.1 of the Food and Drugs Regulations (Data Protection Regulations), Canada did not have an effective regime of data protection exclusivity.


Board follows guidelines in Penlac decision
  • Gowling WLG
  • Canada
  • February 7 2011

On February 3, 2011, the Patented Medicine Prices Review Board (the Board) released its decision dated January 31, 2011, regarding Penlac, a drug manufactured by sanofi-aventis.


Generic drug companies complain about lower prices
  • Gowling WLG
  • Canada
  • September 21 2010

As reported on September 13, 2010 in the National Post, representatives of Canadian generic companies, including Apotex, Teva and the Canadian Generic Pharmaceutical Association are warning that lower prices for generic medicines could backfire.


Provinces and territories discuss joining forces to purchase drugs at lower prices
  • Gowling WLG
  • Canada
  • August 26 2010

On August 6, 2010, Canadian Premiers attended their annual Council of the Federation Premiers' Conference in Winnipeg to discuss a joint alliance among the provinces and territories for purchasing common drugs and medical supplies and equipment for the public sector.


Apotex Inc v. Richter Gedeon Vegyeszeti Gyar Rt
  • Gowling WLG
  • Canada
  • August 25 2010

Plaintiff distributor of pharmaceuticals commenced an action for delayed market entry against Defendant manufacturers of pharmaceuticals for various losses.


Health Canada releases final guidance on biosimilars
  • Gowling WLG
  • Canada
  • March 25 2010

On March 8, 2010, Health Canada released its final guidance documents relating to the approval pathway for subsequent entry biologics (SEBs) in Canada.


New disclosure requirements for clinical trials
  • Gowling WLG
  • Global
  • December 3 2009

The International Federation of Pharmaceutical Manufactures and Associations (IFPMA) has released its latest Joint Position which will require member companies to disclose information on all clinical trials in patients.


U.S. FDA contemplates new rules for internet-delivered health information
  • Gowling WLG
  • USA
  • December 3 2009

In recognition of the increasing use of the Internet by consumers for health-related information, the FDA is seeking to determine whether it needs to regulate the promotion of drugs and medical devices on the Internet.


Second phase of Alberta's pharmaceutical strategy aims to reduce drug costs, improve access to new drugs and expand the role of pharmacists
  • Gowling WLG
  • Canada
  • November 2 2009

On October 20, 2009, the Alberta Government released the second phase of the Alberta Pharmaceutical Strategy which indicates that the Government will reduce generic drug prices - the Government states it will reduce the price of new generic drugs from 75 percent of the brand name drug to 45 and announces that its discussions with pharmacists and pharmacies regarding the price reduction will begin this month.